CompanyIONSNasdaqCarlsbad, CA

Ionis Pharmaceuticals

Ionis develops RNA-targeted medicines and gene editing approaches for neurology and cardiometabolic diseases.

SEC EDGAR ClinicalTrials.gov ionis.com

DEF 14ASep 28Latest SEC filing

Sep 29Latest story

September 2026

Ionis amends REVEAL Phase 3 for obudanersen in Angelman syndrome to two-arm design

Sep 29Weekly roundup, 2 itemsIonis Pharmaceuticals obudanersenUpdated

Ionis and Roche report positive Phase 3 interim data for sefaxersen in IgA nephropathy

Sep 23Clinical readoutIonis Pharmaceuticals Roche

Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 study

Sep 4Clinical readoutIonis Pharmaceuticals Novartis

FDA approves Ionis's ZANVASTRO for Alexander disease

Sep 4Regulatory milestoneIonis Pharmaceuticals zilganersen

FDA approval file confirms Zanvastro details for Alexander disease

Sep 3Regulatory decisionIonis Pharmaceuticals zilganersen

August 2026

Ionis registers Phase 3 trial of obudanersen for Angelman syndrome due to UPD or imprinting defects

Aug 24Trial updateIonis Pharmaceuticals obudanersen

July 2026

Ionis posts Q2 2026 results, flags second-half pipeline milestones

Jul 29Quarterly updatedonidalorsen Ionis Pharmaceuticals

Ionis registers Phase 3 pediatric study of olezarsen for FCS

Jul 27Trial updateIonis Pharmaceuticals olezarsen

Ionis and AstraZeneca's eplontersen misses primary endpoint in Phase 3 ATTR-CM trial

Jul 9Clinical readoutAstraZeneca eplontersen